Provided by Tiger Fintech (Singapore) Pte. Ltd.

EyePoint

6.33
+0.25004.11%
Volume:459.24K
Turnover:2.84M
Market Cap:432.03M
PE:-3.10
High:6.48
Open:6.24
Low:5.94
Close:6.08
Loading ...

Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?

Zacks
·
11 Feb

EyePoint Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
06 Feb

BUZZ-EyePoint Pharma rises on eye disease drug trial data

Reuters
·
05 Feb

EyePoint Pharmaceuticals: An Undervalued Opportunity Amid Market Overreaction and Financing Concerns

TIPRANKS
·
05 Feb

EyePoint's Phase 2 Trial of Duravyu to Treat Diabetic Macular Edema Meets Endpoints; Shares Still Slump Pre-Bell

MT Newswires Live
·
05 Feb

Collegium Pharmaceutical Expands Board with Nancy Lurker

TIPRANKS
·
05 Feb

Collegium appoints Nancy Lurker to board of directors

TIPRANKS
·
05 Feb

Top Premarket Decliners

MT Newswires Live
·
05 Feb

EyePoint announces Phase 2 VERONA trial met primary endpoint

TIPRANKS
·
05 Feb

EyePoint Announces Positive Six-Month Results for the Phase 2 Verona Clinical Trial of Duravyu™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

THOMSON REUTERS
·
05 Feb

EyePoint Pharmaceuticals Inc - No Duravyu-Related Ocular or Systemic Saes Reported

THOMSON REUTERS
·
05 Feb

EyePoint Pharmaceuticals Inc - Primary Endpoint Achieved by Both Duravyu Doses

THOMSON REUTERS
·
05 Feb

EyePoint Pharmaceuticals Inc: Phase 3 Non-Inferiority Pivotal Program Initiation Anticipated by End of 2025 -

THOMSON REUTERS
·
05 Feb

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

GlobeNewswire
·
05 Feb

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

GlobeNewswire
·
30 Jan

EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
16 Jan